HC Wainwright & Co. Reiterates Buy on Karuna Therapeutics, Maintains $300 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Karuna Therapeutics (NASDAQ:KRTX) and maintains a $300 price target.
June 02, 2023 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Karuna Therapeutics and maintains a $300 price target.
The reiterated Buy rating and maintained $300 price target by HC Wainwright & Co. analyst Raghuram Selvaraju on Karuna Therapeutics (KRTX) indicates a positive outlook for the stock. This news is likely to have a positive impact on KRTX's stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100